On Thursday, Following Stocks were among the “Top 100 Gainers” of U.S. Stock Market: Essex Rental Corp. (NASDAQ:ESSX), Amicus Therapeutics, Inc. (NASDAQ:FOLD), Nevro Corp. (NYSE:NVRO)

Essex Rental Corp. (NASDAQ:ESSX), with shares inclined 40.74%, closed at $1.14.

Amicus Therapeutics, Inc. (NASDAQ:FOLD), with shares jumped 33.26%, settled at $33.26.

Nevro Corp. (NYSE:NVRO), surged 18.42%, and closed at $50.01.

Latest NEWS regarding these Stocks are depicted underneath:

Essex Rental Corp. (NASDAQ:ESSX)

Essex Rental Corp. (ESSX), skyrocketed 40.74%, and closed at $1.14. The stock has price to sale ratio of 0.29, however, price to book ratio is 0.49. With recent incline, the year-to-date (YTD) performance reflected a -13.64% decline below last year. During the past month the stock lost -2.56%, bringing three-month performance to -10.46% and six-month performance to -49.11%. The mean recommendation of analysts for this stock is 3. (where 1=Buy, 5=Sale).

Essex Rental Corp., through its auxiliaries, rents and distributes lifting equipment to the construction industry in North America. The corporation operates in three segments: Equipment Rentals, Equipment Distribution, and Parts and Service.

Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Amicus Therapeutics, Inc. (FOLD), declared that it will seek accelerated U.S. approval for its Fabry disease therapy, migalastat, following a productive meeting with the FDA.

The corporation anticipates to submit its application for approval in the second half of this year, ahead of the expectations of many analysts’, according to TheStreet’s Adam Feuerstein. Amicus will also seek European regulatory approval for the drug in the second quarter this year, also ahead of expectations.

If approved, migalastat will be the first oral therapy for Fabry disease, a rare, inherited genetic mutation that stops bodily enzymes from breaking down a fatty substance known as globotriaosylceramide, or GL3, a buildup of which could cause severe damage to kidneys, heart, brain and other organ systems. Fabry disease affects about 10,000 people worldwide.

Amicus Therapeutics, Inc., a biopharmaceutical corporation, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases.

Nevro Corp. (NYSE:NVRO)

Nevro Corp. (NVRO), a medical device corporation that has developed and commercialized an innovative, evidence-based neuromodulation platform for the treatment of chronic pain, stated financial results for the three months and full year ended December 31, 2014.

Recent Accomplishments & Highlights:

• In November 2014, accomplished initial public offering, receiving net proceeds of about $131 million.
• Proceed of $9.7 million in the fourth quarter of 2014, an raise of 57% over the same period of the preceding year.
• In January 2015, received an approvable letter from the U.S. Food & Drug Administration (FDA) in response to the corporation’s pre-market approval (PMA) application for the Senza Spinal Cord Stimulator (SCS) System.

The corporation estimates international proceed for the full year 2015 to be in a range of $36-38 million, which would represent an 11 to 17 percent raise as compared to 2014.

Nevro Corp., a medical device corporation, develops and commercializes a neuromodulation platform for the treatment of chronic pain. It offers Senza system, a spinal cord stimulation system that delivers its proprietary HF10 therapy.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.